

# **L&G Pharma Breakthrough UCITS ETF**

## **FUND SUPPLEMENT**

**No. 18**

*A sub-fund of Legal & General UCITS ETF Plc, an umbrella investment company with variable capital and segregated liability between its Funds incorporated with limited liability in Ireland under registration number 459936.*

The Company and the Directors, whose names appear on page 10 of the Prospectus, are the persons responsible for the information contained in this Fund Supplement and accept responsibility accordingly. To the best of the knowledge and belief of the Company and the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of the information.

This Fund Supplement contains information relating to the L&G Pharma Breakthrough UCITS ETF (the “Fund”) which is a separate Fund of Legal & General UCITS ETF Plc (the “Company”), an umbrella fund with segregated liability between its Funds. This Fund Supplement forms part of and should be read in the context of, and together with, the Company’s Prospectus dated 20 April 2020 and any other applicable addenda. Investors should also refer to the Company’s latest published annual report and audited financial statements (if any) and, if published after such report, a copy of the latest semi-annual report and unaudited financial statements. Capitalised expressions used and not defined in this Fund Supplement shall bear the meanings as set out in the Prospectus. If you are in any doubt about the action to be taken or the contents of this Fund Supplement, please consult your stockbroker, bank manager, lawyer, accountant or other independent professional adviser who, if such advice is taken in the United Kingdom, is an organisation or firm authorised or exempted pursuant to the FSMA.

Potential investors should consider the risk factors set out in the Prospectus and in this Fund Supplement before investing in this Fund. An investment in the Fund involves certain risks and may only be suitable for persons who are able to assume the risk of losing their entire investment.

The Prospectus sets forth information on investment risk, management and administration of the Fund, valuation, subscription, redemption and transfer procedures and details of fees and expenses payable by the Fund and should be read subject to the information herein.

An investment in the Fund should not constitute a substantial proportion of an investment portfolio and may not be appropriate for all investors.

---

The date of this Fund Supplement is 17 February 2021.

---

## INVESTMENT OBJECTIVE

The investment objective of the L&G Pharma Breakthrough UCITS ETF (the “Fund”) is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs.

## INVESTMENT POLICY

In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”), subject to the deduction of the TER and other expenses associated with operating the Fund as further described in the “Fees and Expenses” section of the Prospectus. It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may **have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.**

Where it is not possible or practicable for the Fund to invest directly in all of the component securities of the Index (for reasons such as, but not limited to, where this would involve difficulties or substantial costs, where one or more securities in the Index becomes temporarily illiquid or unavailable, or as a result of legal restrictions or regulatory limitations that apply to the Fund but not the Index) and/or where consistent with its investment objective, the Fund may also invest in the following additional assets subject to the conditions and within the limits laid down by the Central Bank:

- equity securities of companies involved in the bio-technology sector that are not component securities of the Index, but the risk and return characteristics of which, individually or collectively, closely resemble the risk and return characteristics of constituents of the Index or of the Index as a whole;
- Depositary Receipts relating either to component securities of the Index or to equity securities of the type referred to in the bullet point immediately above; and
- FDIs – namely, total return “unfunded” OTC Swaps and exchange-traded equity futures – which may be used for investment purposes (such as gaining exposure to the Index and/or any particular constituents of the Index) in accordance with the terms set out in the sections entitled “Fund Investments”, “Unfunded OTC Swap Model” and Schedule II of the Prospectus. While the Fund may invest up to 100% of its Net Asset Value in total return “unfunded” OTC Swaps, it is not expected that this flexibility will be used. The Fund will only invest in FDIs as provided for in the RMP prepared by the Investment Manager in respect of the Fund and filed with the Central Bank.

The Fund may, in addition, employ other techniques relating to transferable securities, including investing in repurchase and reverse repurchase transactions and short term money market collective investment schemes, for the purpose of efficient portfolio management only, in accordance with the terms set out in the section entitled “Efficient Portfolio Management Techniques” and Schedule II of the Prospectus. While the Fund may invest up to 100% of its Net Asset Value in repurchase and reverse repurchase transactions it is not expected that this flexibility will be used.

## TRACKING ERROR

The estimated anticipated tracking error for the Fund in normal market conditions is 0.75% (annualised).

## SUSTAINABILITY

The Fund has a sustainable objective as it invests in companies which (i) contribute to a social objective, (ii) do not significantly harm any environmental or social objectives and its investee companies follow good governance practices. The investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund is passively managed and pursues its investment objective by seeking to track the performance of the Index. The Index differs from a broad market index as it seeks to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs that treat rare diseases. Further information on the Index can be found in the “*Index Description*” section below, and at <https://www.solactive.com/?s=Solactive%20Biotechnology&index=DE000SLA30N4>.

The Manager aims to ensure that the issuers of investments in which the Fund is invested follow good governance practices. This is achieved by 1) setting expectations with the issuers' management with regard to good governance practices; 2) active engagement with the issuers; 3) utilising its voting rights; and 4) supporting policymakers and legislators to ensure a strong regulatory environment and standards. Active engagement with the issuers is used as a tool to drive progress and influence positive change and is conducted independently and in collaboration with industry peers and broader stakeholders. Engagement activities normally focus on specific material ESG issues and involve formulating an engagement strategy with regard to such issues with the aim to track and review the progress of the issuers during this process. Regular reporting on the outcomes of active engagement can be made available on request or can be found at: [www.lgim.com](http://www.lgim.com).

## INDEX DESCRIPTION

The Index is designed to provide exposure to publically traded bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders.

The constituents of the Index are selected and weighted according to the step-by-step construction process described below. The Index is constructed primarily by reference to stocks of companies that meet certain size and liquidity requirements using a two-fold approach that is primarily based on the trend in the valuation of a company's orphan drug portfolio and its net assets.

The Index is administered and calculated by Solactive AG (the “**Index Administrator**”).

### Determination of the Index Universe

Companies whose securities are eligible for inclusion in the Index Universe are determined by the Index Administrator in accordance with the process described in the Index methodology, which is available at <https://www.solactive.com/?s=Solactive%20Biotechnology&index=DE000SLA30N4>.

1. To be eligible for inclusion in the Index, a security (each an “**Eligible Security**”) must have:
  - 1.1 its primary listing on one of the global stock exchanges listed in Annex A of the Index methodology;
  - 1.2 a minimum free-float adjusted market capitalisation of USD 200 million, unless such security is an existing constituent of the Index. However, if a security is an existing constituent of the Index, the relevant company must have a minimum free float adjusted market capitalisation of USD 150 million to be selected for inclusion. “Free-float adjusted market capitalisation” is a measure of the total market value of the proportion of a company's shares that are publically traded (i.e. “floating”) in the stock market as opposed to locked-in shares held by promoters, company officers, controlling-interest investors, or government authorities;

- 1.3 a minimum three-month average daily value traded of USD 1,000,000; and
  - 1.4 at least one orphan drug that is currently being manufactured and marketed and the share of the relevant company's revenues attributable to orphan drugs expressed as a percentage of the company's total revenues (the "**Orphan Drug Revenue Share**") must be greater than zero.
2. The following selection criteria are then applied to each Eligible Security in order to determine the final Index selection:
- 2.1 In respect of each Eligible Security, the Orphan Drug Revenue Share must be above the median of the Orphan Drug Revenue Share of all Eligible Securities.
  - 2.2 In respect of each Eligible Security, the relevant company must have at least two (2) orphan drugs that are currently being manufactured and marketed.
  - 2.3 In respect of each Eligible Security:
    - 2.3.1 the year-on-year change in the aggregate net present value of the company that is attributable to orphan drugs is greater than zero; or
    - 2.3.2 the estimated net asset value of the relevant company is greater than the net asset value of such company as published in its most recent annual report.
  - 2.4 Finally, if the total number of Eligible Securities included in the final Index selection would be less than fifteen (15), then the above procedure shall be repeated without Step 2.1.

#### Weighting allocation

All Eligible Securities that are included in the final Index selection are equally weighted within the Index.

#### Net Total Return

Total return indices measure the market performance, including price performance and income from regular cash distributions (cash dividends or capital repayments). This income is treated as being reinvested in the Index and thus makes up part of the total index performance. The Index is a *net* total return index which means that cash dividends declared by Index constituents are reinvested in the Index net of withholding tax at the rates (depending on the country of domicile of the Index constituent) set out in the "*Withholding Tax Rates*" table available at: <https://www.solactive.com/news/documents/>.

#### Rebalancing Frequency

The Index Universe shall be determined on an annual basis in March.

Whilst the Index Universe is determined on an annual basis in March, the Index itself shall be reconstituted semi-annually in March and September in accordance with the full selection and weighting parameters described above. At the time of each semi-annual reconstitution of the Index, it is possible that additional companies not presently represented in the Index will be added, or that one or more companies presently represented will be removed.

In addition to the semi-annual reconstitutions of the Index, the weights of the individual constituents of the Index are assessed on a monthly basis. If the weight of an individual security exceeds 15% of the Index at the monthly assessment date, the Index shall be re-weighted in accordance with the above with the result that all component securities are again equally weighted within the Index. If none of the component securities has a weight exceeding 15%, then no re-weighting shall be made.

Investors should note that the respective weights of each of the constituents of the Index are expected to fluctuate in-between the monthly re-weightings and/or semi-annual reconstitutions of the Index.

Further Information

The information set out above is a summary of the principal features of the Index and does not purport to be an exhaustive description. Further information with respect to the component selection criteria, calculation and rebalancing methodology and treatment of corporate events can be found in the “*Index Methodology*” -Solactive Pharma Breakthrough Value Index which (as of the date of this Fund Supplement) is available, along with the constituents and weightings of the Index and various other informational materials, at:

<https://www.solactive.com/?s=Solactive%20Biotechnology&index=DE000SLA30N4>.

	ISIN	Bloomberg	Reuters
<b>Index</b> Solactive Pharma Breakthrough Value Index Net Total Return	DE000SLA30N4	SOLBIOT	.SOLBIOT

As at the date of this Fund Supplement, Solactive AG is listed as a registered benchmarks administrator on the public register maintained by ESMA under the Benchmark Regulation.

Portfolio Composition

The portfolio of Investments held by the Fund is available daily at <http://lgimETF.com>.

**PROFILE OF A TYPICAL INVESTOR**

Only Authorised Participants may purchase ETF Shares in the Fund directly from the Company. All other investors may acquire or purchase ETF Shares only through the secondary market.

It is expected that investors in the Fund will be informed investors who have taken professional advice and who understand (and are able to bear) the risk of losing their investment and who can accept the levels of risks associated with investing in global equity markets, in particular in bio-technology companies.

**RISK MANAGEMENT**

The Fund’s global exposure, being the incremental exposure and leverage generated by the Fund through its use of FDI, shall be calculated on at least a daily basis using the commitment approach and, in accordance with the requirements of the Central Bank, may at no time exceed 100% of the Fund’s Net Asset Value. As noted in the “*Investment Policy*” section above, the Fund’s use of FDI is an ancillary element of the investment policy in that it is an alternative means of gaining exposure to the Index, or one or more of the constituents of the Index, in circumstances where direct investment in the constituents of the Index is not possible, practicable or desirable. Regardless of whether exposure to the underlying constituents is obtained by direct investment in the constituents, or by gaining exposure to the constituents through the use of FDI, the same notional value shall be committed to the investment by the Fund. Accordingly, it is not expected that the Fund will be leveraged.

**RISK FACTORS**

Investors are specifically referred both to the section headed “*Risk Factors*” and to Schedule II in the Prospectus and should consider the following risk factors prior to investing in the Fund.

1. An investment in the Fund exposes an investor to the market risks associated with fluctuations in the Index and the value of securities comprised in the Index. The value of the Index can increase as well as decrease and the value of an investment will fluctuate accordingly. Investors can lose all of the capital invested in the Fund.

2. The Fund invests primarily in the equity securities of pharmaceutical companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. Accordingly, the Fund is particularly sensitive to risks relating to those types of companies. In particular, pharmaceutical companies are subject to, but not limited to, the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production as a result of, inter alia, (i) clinical trial failures, (ii) governmental intervention or refusal to grant appropriate approvals and/or licenses for clinical trials or commercial production and/or (iii) a lack of commercial viability. Additionally, even if an orphan drug successfully enters into commercial production, the emergence of cheaper or more effective drugs could lead to a decline in the revenues of the relevant orphan drug-producing company in respect thereof. Further, each company may derive some or a substantial portion of its revenues from business segments that may be unrelated to the research, development and/or manufacturing of orphan drugs. As a result, such companies shall also be subject to risks that are typically associated with such other business segments. All of the foregoing may lead to a decline in the value of such companies as represented within the Index and owned by the Fund.
  
3. The Index is typically comprised of a mix of micro, small, mid and large cap companies. The terms “micro cap”, “small cap”, “mid cap” and “large cap” refer to the “market capitalisation” of a company’s shares which is a measure of the total market value of a company’s shares. Micro cap small cap and mid cap companies may be more vulnerable to adverse business or economic events than large cap companies which are typically larger, more established companies. In particular, micro cap, small cap and mid cap companies generally trade in lower volumes, are often more vulnerable to market volatility and are subject to greater and more unpredictable price changes than large cap stocks or the stock market as a whole.

## THE SHARES

As at the date of this Fund Supplement, the Fund only has a single class of Shares which are ETF Shares as detailed in the table below. Additional classes of Shares may be added in the future in accordance with the requirements of the Central Bank.

Shares are freely transferable subject to and in accordance with the provisions of the Articles and as set out in the Prospectus.

As with other Irish companies limited by shares, the Company is required to maintain a register of Shareholders. ETF Shares will be held by the Common Depository’s Nominee (as registered holder) in registered form. Only persons appearing on the register of Shareholders (i.e. the Common Depository’s Nominee) will be a Shareholder. Fractional Shares will not be issued. No temporary documents of title or Share certificates will be issued (save for the Global Share Certificate, as set out in the Prospectus). A trade confirmation will be sent by the Administrator to the Authorised Participants.

Share Class	Share Class Type	Minimum Subscription / Redemption Amount	TER*	Dividend policy
USD Accumulating ETF	ETF Shares	50,000 Shares	0.49%	N/A

\*Expressed as a % per annum of the Net Asset Value of the Share class.

## STOCK EXCHANGE LISTINGS

Application has been made to the stock exchange(s) listed below for the admission to trading of the specified class of ETF Shares. Applications for the admission to additional stock exchanges of existing and new classes of ETF Shares may be made from time to time.

Share Class	Share Class Type	Listing Exchange	Listing Currency	ISIN	Bloomberg code	Reuters code
-------------	------------------	------------------	------------------	------	----------------	--------------

USD Accumulating	ETF Shares	London Stock Exchange	USD	IE00BF0H7608	BIOT LN	GEBIOT.L
		London Stock Exchange	GBP	IE00BF0H7608	BIGT LN	BIGT.L
		Borsa Italiana	EUR	IE00BF0H7608	BIOT IM	ECBIOT.MI
		Deutsche Börse	EUR	DE000A2H9VJ3	ETLI GY	ETLI.DE
		NYSE Euronext	EUR	IE00BF0H7608	BIOT NA	GOBIOT.AS

## DEALING PROCEDURES

The procedures for subscribing for and redeeming of Shares are outlined in the Prospectus. Subscriptions and redemptions in the Fund may be in cash or, where agreed with the Manager or its delegate, on an *in specie* basis.

Shares may be subscribed for in the manner set out in the Prospectus under the heading “*Subscriptions*”, beginning on page 55.

Shares in the Fund may be redeemed as described in the Prospectus under the heading “*Redemptions*” beginning on page 63.

In the context of each application for subscription for or redemption of Shares, the Manager (or its appointed delegate) shall have sole discretion as to whether Duties and Charges are charged as a fixed amount or charged to match the exact cost to the Company of purchasing or selling the relevant underlying Investments. Where Duties and Charges are charged as a fixed amount, such fixed amount shall not exceed 5% of Net Asset Value of Shares being applied for or redeemed.

## DEALING INFORMATION

Base Currency	USD
Dealing Currency	The dealing currency for each class of Shares is the currency of denomination of the relevant class of Shares.
Business Day	A day on which banks and markets and exchanges are open for business in the United Kingdom.
Dealing Day	An Index Publication Day and a day on which no Significant Markets are closed for business or such Business Day(s) as the Directors may from time to time determine (subject to advance Shareholder notice) for dealings in the Fund provided always that there shall be at least one Dealing Day each fortnight. The Promoter maintains an online “ <i>Dealing Day Calendar</i> ” at: <a href="http://www.lgimetf.com">http://www.lgimetf.com</a> , where advance notice of all expected Dealing Days for the Fund is published on an ongoing basis. The Dealing Day Calendar is also available on request from the Manager and from the Promoter.
Dealing Deadline	The cut-off time in respect of any Dealing Day for receipt of applications for subscriptions and redemptions in the Fund as shall be set out on <a href="http://www.lgimetf.com">http://www.lgimetf.com</a> , which information shall be kept up to date.
Minimum Subscription Amount	Please refer to the table contained in the section above entitled “ <i>The Shares</i> ”.
Minimum Redemption Amount	Please refer to the table contained in the section above entitled “ <i>The Shares</i> ”.

Settlement Time	<p>Settlement of subscriptions shall generally occur within two Business Days after the relevant Dealing Day (unless otherwise agreed with the Manager or its delegate).</p> <p>Settlement of redemptions shall generally occur within two Business Days after the relevant Dealing Day (unless otherwise agreed with the Manager or its delegate).</p>
Valuation	<p>The Valuation Point is the time at which the value of the Index is determined.</p> <p>Investments of the Fund which are listed or traded on a Regulated Market for which quotations are readily available shall, subject to the provisions of the Articles, be valued at the last traded price.</p>
TER	<p>Please refer to the table contained in the section above entitled "<i>The Shares</i>" for the TER applicable to each Share class.</p> <p>Brokerage and extraordinary expenses are excluded from the TER figure – see section entitled "<i>Fees and Expenses</i>" on page 72 of the Prospectus.</p> <p>Fees and expenses relating to the establishment of the Fund are borne by the Manager.</p>

## TAXATION

A description of the taxation applicable to the Company and its investors is outlined under the heading "*Taxation*" in the Prospectus.

### **German Tax Information**

The Company seeks to maintain "equity fund" status for the Fund pursuant to Section 2 para. 6 and 7 of the German Investment Tax Act 2018.

Investors should consult their own professional advisers as to the implications of the Fund maintaining "equity fund" status pursuant to the German Investment Tax Act 2018.

As at the date of this Fund Supplement, at least 51% of the Fund's assets will be continuously invested in equity assets as defined in Section 2. para. 8 of the German Investment Tax Act 2018.

## INDEX DISCLAIMER

The Fund is not sponsored, promoted, sold or supported by the Solactive AG. Nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index price, at any time or in any other respect.

The Index is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Company, Solactive AG has no obligation to point out errors in the Index to third parties including, but not limited to, investors and/or financial intermediaries of the Fund. Solactive AG does not guarantee the accuracy and/or the completeness of the Index or any related data, and shall not have any liability for any errors, omissions or interruptions therein.

Neither publication of the Index by Solactive AG, nor the licensing of the Index or Index trade mark, for the purpose of use in connection with the Fund, constitutes a recommendation by Solactive AG to invest capital in said Fund nor does it, in any way, represent an assurance or opinion of Solactive AG with regard to any investment in this Fund. In no event shall Solactive AG have any liability for any loss

profits or indirect, punitive, special or consequential damages or losses, even if notified of the possibility thereof.

WF-28734742-4